pCDCAR1 CD20 h(28γ), T(CAR-T-2-M302-2G)
The vector of anti-CD20 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD20. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD20 antibody linked to CD28 transmembrane domain/ endodomain and FcεRIγ signaling domains. And the vector product was designed for the treatment of CD20 +malignancies, B-cell lymphoma, mantle cell lymphoma, CD20+ diffuse large cell lymphoma (DLCL), leukemias.
Targeting Cell Type
CD20+ malignancies; B-cell lymphoma; mantle cell lymphoma; CD20+ diffuse large cell lymphoma (DLCL); leukemias
Discription of Signaling Cassetes
CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatorysignals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells(APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
The high-affinity IgE receptor, also known as FcεRI, or Fc epsilon RI, is the high-affinity receptor for the Fc region of immunoglobulin E (IgE). FcεRI is a key molecule involved in allergic reactions. It is a tetramer composed of 1alpha, 1 beta, and 2 gamma chains. The gamma chains are also subunits of other Fc receptors. The scFv-based CARs engineered to contain a signaling domain from FcεRIγ have been shown to deliver a potent signal for T cell activation and function.
membrane-spanning 4-domains, subfamily A, member 1
MS4A1; membrane-spanning 4-domains, subfamily A, member 1; B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; Chronic lymphocytic leukemia; CLL; leukemia; scFv; FcεRIγ; Chimeric antigen receptor; NK cell; Retrovirus; CARs; Lentivirus; chimeric NK cell receptors; chimeric immunoreceptors; chimeric antigen receptors; rituximab
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Anti-CD20 scFv h(CD28-CD3ζ) CART, pCDCAR1
||Anti-CD20 scFv h(CD3ζ) CART, pCDCAR1
||Anti-CD20 (Ofatumumab) h(FcγRIII) CAR, pCDCAR1
||Anti-CD20 scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1
||Lenti-CD20 CAR (scFv-FcεRIγ, 1F5) Viral Particle
||Lenti-CD20 CAR (scFv-CD28-41BB-CD3ζ, 1F5) Viral Particle
||Anti-CD20 (Ofatumumab) h(CD3ζ) CAR, pCDCAR1
||Anti-CD20 scFv h(b2c-CD3ζ) CART, pCDCAR1
||Lenti-CD20 CAR (scFv-CD8-CD3ζ, 1F5) Viral Particle
||Lenti-CD20 CAR (scFv-41BB-CD3ζ, 1F5) Viral Particle